不同酸水解酪蛋白对W135群和Y群脑膜炎奈瑟菌荚膜多糖产量的影响

目的 探索不同酸水解酪蛋白对W135群与Y群脑膜炎奈瑟菌(脑膜炎球菌)荚膜多糖产量的影响。方法 分别以NaCl质量分数为37%和14%的酸水解酪蛋白作为有机氮源配制改良半综合高盐培养基和低盐培养基,利用全自动细菌发酵罐分别在两种培养基里培养W135群和Y群脑膜炎球菌,比较这两种菌株在两种培养基中的生长时间、收获液菌密度( A 600 nm 值)、收获液去菌体后与去复合多糖后上清中的荚膜多糖含量,以及纯化后的精糖产量;比较高盐培养基收获液及其2倍稀释液中不同终含量的十六烷基三甲基溴化铵(cetyltrimethylammonium bromide, CTAB)溶液对多糖沉淀效果的影响。结果 W135群与Y群脑膜炎球菌在两种培养基中的培养时间差异无统计学意义( P >0.05),但高盐培养基收获液的菌密度、收获液去菌体后上清液中的多糖含量均高于低盐培养基收获液,差异有统计学意义( P < 0.05),而高盐培养基收获液纯化后的精糖产量低于低盐培养基,差异有统计学意义( P <0.05)。高盐培养液2倍稀释后,在CTAB终体积分数为0.04%时,W135群与Y群脑膜炎球菌多糖全部沉淀,而未稀释高盐培养液即使CTAB终体积分数提高到0.14%,依然也不能完全沉淀 W135群与Y群脑膜炎球菌多糖。结论 不同酸水解酪蛋白对W135群和Y群脑膜炎球菌的生长密度和荚膜多糖产量有影响,用CTAB溶液沉淀荚膜多糖时需控制收获液盐含量。     

不同的甲醛杀菌浓度对A群、C群脑膜炎球菌荚膜多糖内毒素含量的影响

目的研究不同的甲醛杀菌浓度对A群、C群脑膜炎球菌荚膜多糖内毒素含量的影响。方法将A群脑膜炎球菌发酵液分成A、B两组,A组采用体积分数为2.5%甲醛杀菌,B组采用体积分数为2.0%甲醛杀菌。将C群脑膜炎球菌发酵液分成C、D两组,C组采用体积分数为2.5%甲醛杀菌,D组采用体积分数为2.0%甲醛杀菌。分别纯化获得荚膜多糖,用动态浊度法测定荚膜多糖中内毒素的含量。结果 A、C两组荚膜多糖中内毒素含量显著低于B、D两组荚膜多糖中的内毒素含量(P<0.05)。结论使用不同浓度的甲醛杀菌,对A群、C群脑膜炎球菌荚膜多糖内毒素的含量有显著影响。较高浓度的甲醛利于菌体细胞的固定,从而防止细菌自溶释放内毒素,因而高浓度的甲醛能够减少其内毒素的含量,提高了产品质量。     

A群脑膜炎球菌荚膜多糖纯化工艺的优化

目的对A群脑膜炎球菌荚膜多糖纯化工艺的关键步骤进行分步研究,优化每一步工艺参数。方法优化十六烷基三甲基溴化铵的加入浓度、复合多糖的解离浓度和解离时间、不同厂家的苯酚、超滤和透析等工艺过程对荚膜多糖的影响。结果十六烷基三甲基溴化铵质量体积终浓度0.10%(w/v)沉淀效果更好,纯化获得的荚膜多糖产量更高相对分子质量更大。复合多糖解离浓度越高,纯化获得的荚膜多糖相对分子质量越小。延长复合多糖解离时间有利于提高荚膜多糖产量。不同厂家的苯酚、超滤和透析等工艺对荚膜多糖的产量和分子大小没有影响。结论现行A群脑膜炎球菌荚膜多糖纯化工艺复杂,优化后的工艺提高了荚膜多糖产量,缩短了工艺用时,增加了工艺稳定性。     

新生隐球菌GXM的纯化及其对巨噬细胞甘露糖受体表达调节的研究

目的从新生隐球菌B3501培养上清中分离和纯化荚膜多糖葡萄糖醛酸木糖甘露聚糖(GXM),观察其是否能调节巨噬细胞甘露糖受体MR的表达。方法采用乙醇沉淀荚膜多糖,十六烷基三甲基溴化铵(CTAB)特异性沉淀方法获得GXM,将GXM与巨噬细胞共孵育24 h,Western blot检测MR的表达变化情况。结果获得了毫克级的GXM,巨噬细胞与GXM孵育后甘露糖受体(mannose receptor,MR)的表达没有明显变化。结论新生隐球菌荚膜多糖GXM不影响巨噬细胞甘露糖受体MR的表达。     

乙醇、丙酮和氯化钙对W135群脑膜炎球菌荚膜多糖唾液酸含量检测的影响

目的研究乙醇、丙酮和氯化钙是否影响间苯二酚法测定W135群脑膜炎球菌荚膜多糖(group W135 meningococcal capsular polysaccharide)唾液酸(sialic acid)含量。方法用苯酚法制备W135群脑膜炎球菌荚膜多糖;分别定量检测唾液酸和W135群脑膜炎球菌荚膜多糖添加不同质量浓度乙醇、丙酮和氯化钙,用间苯二酚法测定其唾液酸含量,检测乙醇、丙酮和氯化钙对间苯二酚测定唾液酸含量的影响。结果添加质量浓度≥39.5μg/mL的乙醇和≥9.9μg/mL的丙酮对唾液酸含量测定均有影响,其中乙醇影响不明显,丙酮的影响极为明显,而不同加入量的氯化钙均对唾液酸含量的测定无影响。结论乙醇和丙酮对间苯二酚法测定唾液酸含量有影响,二者可能会对W135群脑膜炎球菌荚膜多糖质量控制产生影响。     

脑膜炎球菌荚膜多糖氧乙酰基相关特性及其作用机理

氧乙酰基(O-acetyl,OAc)存在于许多细菌多糖中,如脑膜炎球菌(meningococcus)A、C、W135、Y群荚膜多糖、大肠杆菌K1型荚膜多糖等均存在氧乙酰化修饰。由于荚膜多糖(capsular polysaccharides, CPS)中OAc的分布和占比被视为脑膜炎球菌多糖候选疫苗的关键质量控制因素,氧乙酰化修饰对多糖疫苗的免疫原性的重要作用,特别是脑膜炎球菌CPS OAc对其疫苗免疫原性的影响越来越受到关注。现就脑膜炎球菌CPS OAc的相关特性和检测方法、迁移因素、OAc修饰及其作用、OAc转移酶的作用机制、OAc对脑膜炎球菌免疫原性的影响作一概述,有助于脑膜炎球菌荚膜多糖疫苗安全性和免疫原性的评价。     

溶氧浓度对A群脑膜炎球菌荚膜多糖产量及质量的影响

目的研究不同溶氧(dissolved oxygen, DO)浓度对A群脑膜炎球菌(Meningococci group A)荚膜多糖产量及质量的影响,确定A群脑膜炎球菌发酵时的最适DO浓度。方法通过调整发酵罐搅拌转速,通气量和罐内压力,使得A群脑膜炎球菌发酵时发酵液中的DO浓度分别为5%、10%、20%和30%,测定不同DO浓度细菌的生长情况、葡萄糖和氢氧化钠消耗情况,发酵结束后从发酵液中提纯荚膜多糖,比较不同DO浓度荚膜多糖的产量和质量。结果 DO浓度对A群脑膜炎球菌的生长及代谢影响显著,当DO浓度为20%时,发酵液中细菌的终浓度是DO浓度5%的1.9倍,是DO浓度10%的1.3倍;发酵液中的葡萄糖消耗速率和氢氧化钠的用量均随着DO浓度的升高而降低。DO浓度对A群脑膜炎球菌荚膜多糖的产量及质量也有明显影响。当DO浓度为20%时,A群脑膜炎球菌荚膜多糖产量是DO浓度为5%的3倍,是DO浓度为10%的1.7倍;荚膜多糖细菌内毒素含量较DO浓度为5%下降78%,较DO浓度为10%下降64%;分子大小也优于其他溶氧浓度。结论 DO浓度为20%是A群脑膜炎球菌发酵时的最适DO浓度。     

W135群脑膜炎球菌发酵工艺的研究

为研究A、C、Y、W 135群流脑多糖疫苗,针对W 135群脑膜炎球菌的生长特性,采用国产50L发酵罐,针对流脑半综合液体培养基中葡萄糖浓度;培养温度、菌种接种浓度、pH、通氧量及搅拌速度等因素对W 135群脑膜炎球菌生长的影响,选择最适的培养条件。结果表明,选择半综合培养基中补加1%的葡萄糖培养效果良好,菌种接种浓度直接影响多糖复合物产量;最适pH值6.5~7.5的范围可维持W 135群链球菌快速生长;温度控制在36.5±0.2℃可得到较高的培养产物;培养过程中加大通气量及搅拌速度对培养结果有明显改善。确立了W 135群脑膜炎球菌的最适培养条件,在确定培养条件后连续进行3批500L罐放大中试培养,达到规模化生产要求。     

6A型肺炎球菌结合物分子大小对小鼠免疫原性的影响

目的 比较不同分子大小的6A型肺炎球菌(serotype 6A Streptococcus Pneumoniae )结合物和佐剂吸附在小鼠体内免疫原性的影响。方法 通过乙酸水解降低6A型荚膜多糖的相对分子质量制备成水解物,水解物经1-氰基-4-二甲胺基吡啶四氟硼酸盐(CDAP)活化并与破伤风类毒素己二酸酰肼衍生物TT AH 结合,制备成结合物。用Sepharose 4 Fast Flow 纯化结合物,并根据化学检测结果将结合物分为 K D 0.0~0.2、 K D 0.2~0.4、 K D 0.4~0.6等3个组分,每个组分分别以磷酸铝佐剂吸附,将吸附前后的各个组分按照每针次每只小鼠0.2 μg分别免疫小鼠,并采用ELISA检测结合物在小鼠体内的抗体水平。结果 3种不同相对分子质量吸附前后的结合物在小鼠体内均能产生较高水平的抗体,各组2、3针之间具有明显的加强效应。在吸附组和未吸附组中,3种不同分子大小的结合物在小鼠体内产生抗体水平无明显差异。各组分佐剂吸附后的结合物血清抗体滴度高于未吸附组,但这种差异无统计学意义( P > 0.05)。结论 结合物的分子大小对小鼠体内抗体水平的产生没有明显影响;磷酸铝佐剂吸附对于不同分子大小的结合物在小鼠体内的免疫原性有一定的增强效应,但这种增强效应差异无统计学意义。     

肺炎链球菌5型发酵工艺的优化

目的:采用正交试验设计方法进行肺炎链球菌5型发酵工艺的研究。方法:根据正交试验设计表L9(34)设计的试验条件组合进行了9次肺炎链球菌5型的发酵,采用70升发酵罐进行发酵工艺的摸索,提取了肺炎链球菌5型荚膜多糖粗糖。结果:最佳的发酵培养条件组合为温度37℃、葡萄糖20克/升、大豆胨15克/升、pH值7.3,最佳的纯化条件组合为冷酚抽提三次、沉核酸乙醇浓度23%、超滤膜孔径50kD、最终沉糖乙醇浓度60%,在此筛选得到的最佳条件下,连续进行了5个批次肺炎链球菌5型的发酵与荚膜多糖提取,荚膜多糖粗糖的平均收率为808.6mg/L,相对标准偏差为3.84%。结论:上述发酵培养条件组合适合用于肺炎多糖疫苗的研究和生产。     

Control of meningococcal meningitis with meningococcal vaccines.

The development of effective meinigococcal vaccines was based upon the finding that immunity to the meningococcus was directly correlated with serum bactericidal antibodies. Purified high molecular weight capsular polysaccharides of serogroups A and C meningococci stimulated the production of humoral antibodies which had group specific bactericidal activity. In controlled field trials in Army recruits, group C polysaccharide vaccines were highly effective in preventing group C disease. Following its use as a routine immunization in recruits in October 1971 group C meningococcal disease has been almost completely eliminated from Army training centers. Group A vaccine has been field tested in Egyptian school children with great success. Group B polysaccharide has failed to induce bactericidal antibodies in humans and, therefore, new research is underway to attempt to develop a cell wall protein antigen as a vaccine against group B disease.     

Cell-free biosynthesis of the O-acetylated N-acetylneuraminic acid capsular polysaccharide of group C meningococci.

A cell-free system was established to study the biosynthesis of group C meningococcal capsular polysaccharide, an alpha-2 leads to 9-linked N-acetylneuraminic acid (NeuAc) homopolymer containing O-acetyl groups at either C7 or C8. Sialyltransferase activity, isolated from group C meningococcus strain C-11, catalyzed incorporation of [14C]NeuAc from CMP (CMP--[14C]NeuAc) into polymeric form. This sialyltransferase was stimulated by addition of meningococcus group C and Escherichia coli K92 capsular polysaccharides, the latter being an alpha-2 leads to 8- and alpha-2 leads to 9-linked NeuAc heteropolymer. Group C meningococcal sialyltransferase did not require divalent ions but was stimulated by Mn2+. Attempts to demonstrate a lipid-soluble intermediate in the biosynthesis of this NeuAc polymer were unsuccessful. Meningococcal group C sialyltransferase incorporated NeuAc into a membrane-associated product. The polysaccharide can be extracted from the membrane-bound fraction with Triton X-100. The newly synthesized polysaccharide coprecipitates with authentic group C antigen in meningococcal group C antiserum and is degraded by sodium metaperiodate, indicating that the NeuAc polymer synthesized by the cell-free system consists of alpha-2 leads to 9 linkage. Meningococcal group C spheroplast membranes contain an O-acetylase that can catalyze the transfer of acetyl groups from acetyl coenzyme A to the in vitro-synthesized polysaccharide.     

B群脑膜炎球菌疫苗的研制策略

脑膜炎奈瑟菌主要引起儿童细菌性脑脊髓膜炎和败血症,有较高的发病率和病死率。现用疫苗能够控制A、C、W135和Y群脑膜炎球菌引起的感染,而由于B群荚膜多糖免疫原性弱,外膜蛋白变异性高等原因,仍无安全和具有广泛保护性的疫苗用于控制B群脑膜炎球菌的感染。目前,B群脑膜炎球菌大多已成为引起发达国家侵袭性脑膜炎疾病的主要病原体。随着研究的不断深入,B群脑膜炎球菌疫苗的研究已经取得了很大的进展,外膜囊(Out membrane vesicles,OMV)疫苗已经在控制特异性菌株爆发流行中取得了成功。然而,人们对具有广泛保护性的B群脑膜炎球菌疫苗的探索仍在继续。本文对近年来B群脑膜炎球菌基于不同型抗原疫苗的各种研制策略及其存在的问题进行了综述。     

The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides.

Recently, we have shown that the capsular polysaccharide of Bacteroides fragilis NCTC 9343 is composed of an aggregate of two discrete large molecular weight polysaccharides (designated polysaccharides A and B). Following disaggregation of this capsular complex by very mild acid treatment, high resolution NMR spectroscopy demonstrated that polysaccharides A and B consist of highly charged repeating unit structures with unusual substituent groups (Baumann, H., Tzianabos, A. O., Brisson, J.-R., Kasper, D.L., and Jennings, H.J. (1992) Biochemistry 31, 4081-4089). Presently, we report that the capsular polysaccharide of B. fragilis represents a complex structure that is formed as a result of ionic interactions between polysaccharides A and B. Electron microscopy of immunogold-labeled organisms (with monoclonal antibodies specific for polysaccharides A and B) demonstrated that the two polysaccharides are co-expressed on the cell surface of B. fragilis. We have shown that the purified capsule complex is made up exclusively of polysaccharide A and polysaccharide B (no other macromolecular structure was detected) in a 1:3.3 ratio and that disaggregation of this complex into the native forms of the constituent polysaccharides could be accomplished by preparative isoelectric focusing. Structural analyses of the native polysaccharides A and B showed that they possessed the same repeating unit structures as the respective acid-derived polysaccharides. The ionic nature of the linkage between polysaccharides A and B was demonstrated by reassociation of the native polysaccharides to form an aggregated polymer comparable to the original complex. The distinctive composition of this macromolecule may provide a rationale for the unusual biologic properties associated with the B. fragilis capsular polysaccharide.     

Phospholipid substitution of capsular polysaccharides and mechanisms of capsule formation in Neisseria meningitidis

Within the capsule gene complex (cps) of Neisseria meningitidis two functional regions B and C are involved in surface translocation of the cytoplasmically synthesized capsular polysaccharide, which is a homopolymer of α-2,8 polyneuraminic acid. The region-C gene products share characteristics with transporter proteins of the ABC (ATP-binding cassette) superfamily of active transporters. For analysis of the role of region B in surface translocation of the capsular polysaccharide we purified the polysaccharides of region B- and region C-defective Escherichia coli clones by affinity chromatography. The molecular weights of the polysaccharides were determined by gel filtration and the polysaccharides were analysed for phospholipid substitution by polyacrylamide gel electrophoresis and immunoblotting. The results indicate that the full-size capsular polysaccharide with a phospholipid anchor is synthesized intracellularly and that lipid modification is a strong requirement for translocation of the poly saccharide to the cell surface. Proteins encoded by region B are involved in phospholipid substitution of the capsular polysaccharide. Nucleotide sequence analysis of region B revealed two open reading frames, which encode proteins with molecular masses of 45.1 and 48.7 kDa.     

基于可见光测定的山羊支原体山羊肺炎亚种抗原定量

山羊支原体山羊肺炎亚种(Mycoplasma capricolum subsp. capripneumoniae, Mccp)是山羊传染性胸膜肺炎(contagious caprine pleuropneumonia, CCPP)的病原,可用灭活疫苗和荚膜多糖(capsular polysaccharide, CPS)间接血凝试剂进行预防和血清学检测,但高昂的培养成本和复杂的抗原定量一直困扰着生产人员。为解决生产实际中出现的这些问题,本研究基于Mccp代谢组学的前期理论基础,通过改变初始pH值的方法,初步筛选出初始pH值为7.8的可以同时提高2种抗原产量的糖发酵培养基。利用紫外可吸收光谱可识别酚红,以及十六烷基三甲基溴化铵(cetyltrimethylammonium bromide, CTAB)可与阴离子荚膜多糖结合的理论依据,建立了利用紫外光谱分析Mccp达到的培养阶段,以及利用CTAB沉淀法相对定量发酵液荚膜多糖抗原产量的方法。通过紫外图谱观察的方法可对应Mccp生长曲线进行指导生产,大大节省传统颜色变化单位(color change unit, CCU)法的监测时间,提高了原肉眼观察方法的精确度。建立的CTAB沉淀法可在5 h内完成对CPS含量的监测,与传统的差值法相比大大缩短了时间,并且其准确度得到苯酚-硫酸法的验证。本研究优化的一种培养基和建立的两种相关性比较方法,可有效降低Mccp生产成本,提高生产效率,这些方法已在本实验室的研究阶段得到应用,为进一步改进CCPP灭活疫苗和荚膜多糖的生产工艺以及快速定量提供了实验数据。     

Monoclonal antibodies against the capsular K antigen of Escherichia coli (O9:K30(A):H12): characterisation and use in analysis of K antigen organisation on the cell surface

Monoclonal antibodies were produced against the capsular antigen of Escherichia coli serotype K(A)30, using a mouse hybridoma system. The antibodies also recognised the chemically identical capsular polysaccharide produced by Klebsiella K20. Chemical modification of the K30 polysaccharide indicated that the glucuronic acid residues found in the E. coli K30 capsular antigen were important in the epitope recognised by these antibodies. Use of the antibodies as molecular probes revealed the presence of two discrete forms of the K30 antigen. One form was comprised of high molecular weight polysaccharide, present as a surface capsular layer. The second form of the antigen was of low molecular weight and was associated with lipopolysaccharide fractions from cell surface polysaccharide extracts. Separation of lipopolysaccharide fractions using gel chromatography in the presence of detergent showed that the low molecular weight K-antigenic fraction comigrated with a lipopolysaccharide lipid A core fraction present in encapsulated E. coli K30 bacteria but absent in acapsular mutants.     

Characterization of the linkage between the type III capsular polysaccharide and the bacterial cell wall of group B Streptococcus

The capsular polysaccharide of group B Streptococcus is a key virulence factor and an important target for protective immune responses. Until now, the nature of the attachment between the capsular polysaccharide and the bacterial cell has been poorly defined. We isolated insoluble cell wall fragments from lysates of type III group B Streptococcus and showed that the complexes contained both capsular polysaccharide and group B carbohydrate covalently bound to peptidoglycan. Treatment with the endo-N-acetylmuramidase mutanolysin released soluble complexes of capsular polysaccharide linked to group B carbohydrate by peptidoglycan fragments. Capsular polysaccharide could be enzymatically cleaved from group B carbohydrate by treatment of the soluble complexes with beta-N-acetylglucosaminidase, which catalyzes hydrolysis of the beta-D-GlcNAc(1-->4)beta-D-MurNAc subunit produced by mutanolysin digestion of peptidoglycan. Evidence from gas chromatography/mass spectrometry and (31)P NMR analysis of the separated polysaccharides supports a model of the group B Streptococcus cell surface in which the group B carbohydrate and the capsular polysaccharide are independently linked to the glycan backbone of cell wall peptidoglycan; group B carbohydrate is linked to N-acetylmuramic acid, and capsular polysaccharide is linked via a phosphodiester bond and an oligosaccharide linker to N-acetylglucosamine.